chr13:28577411:> Detail (hg19) (FLT3)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr13:28,577,411-28,674,729 |
| hg38 | chr13:28,003,274-28,100,592 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| acute myeloid leukemia | B |
Prognostic
|
Does Not Support
|
N/A | Somatic | 2 | 14726504 | Detail | |
| acute myeloid leukemia | Midostaurin | A |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 28546144 | Detail |
| acute myeloid leukemia | Gilteritinib | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 28645776 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetica... | CIViC Evidence | Detail |
| Midostaurin is FDA-approved for the treatment of newly-diagnosed acute myeloid leukemia patients har... | CIViC Evidence | Detail |
| In a phase 1-2 trial, patients with refractory or relapsed AML with FLT3 mutation received gilteriti... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- Genome
- hg19
- Position
- chr13:28,577,411-28,674,729
- Variant Type
- snv
- Variant (CIViC) (CIViC Variant)
- MUTATION
- Transcript 1 (CIViC Variant)
- ENST00000241453.7
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/519
Genome browser